Reports Q1 revenue $93.9M vs $101.5M last year. “As the new CEO of Accuray (ARAY), I have a tremendous amount of respect for what our radiotherapy systems can do to improve cancer patients’ lives for the better. While our first quarter results were soft, we were pleased to see continued expansion of our CyberKnife(R) and Radixact(R) Systems into new hospitals and markets, and we are excited about the introduction of Accuray Stellar and its potential in the U.S., where it is currently available for sale,” said Steve La Neve.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARAY: